Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: Eligibility criteria for NMA_Diabetes - XML Representation

Raw xml | Download


<Group xmlns="http://hl7.org/fhir">
  <id value="264323"/>
  <meta>
    <versionId value="16"/>
    <lastUpdated value="2024-08-01T12:27:35.568Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-eligibility-criteria"/>
  </meta>
  <text>
    <status value="empty"/>
    <div xmlns="http://www.w3.org/1999/xhtml">[No data.]</div>
  </text>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
    <valueContactDetail>
      <name value="Sheyu Li"/>
    </valueContactDetail>
  </extension>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact">
    <valueRelatedArtifact>
      <type value="cite-as"/>
      <citation
                value="Eligibility criteria for NMA_Diabetes [Database Entry: FHIR Group Resource]. Contributors: Sheyu Li [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 264323. Revised 2024-07-30. Available at: https://fevir.net/resources/Group/264323. Computable resource at: https://fevir.net/resources/Group/264323."/>
    </valueRelatedArtifact>
  </extension>
  <url value="https://fevir.net/resources/Group/264323"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="https://fevir.net"/>
    <value value="264323"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <title value="Eligibility criteria for NMA_Diabetes"/>
  <status value="active"/>
  <publisher value="Computable Publishing LLC"/>
  <contact>
    <telecom>
      <system value="email"/>
      <value value="support@computablepublishing.com"/>
    </telecom>
  </contact>
  <description
               value="Eligible randomised controlled trials compared drugs used to treat adults with type 2 diabetes. We considered the following drug classes: SGLT-2 inhibitors, GLP-1 receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones, sulfonylureas, metformin, α-glucosidase inhibitors, meglitinides, insulins, dual GIP/GLP-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists. Appendix 1.3 describes the detailed drug names and definitions of control arms (typically standard treatment at the time the trials were conducted, representing the treatment regimens the patient received before the clinician considered adding a new drug). Eligible trials had a follow-up of 24 weeks or longer. Trials systematically comparing combinations of more than one drug treatment class with no drug treatment, subgroup analyses of randomised controlled trials, and non-English language studies were deemed ineligible."/>
  <copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
  <membership value="conceptual"/>
  <code>
    <text value="Research study"/>
  </code>
  <combinationMethod value="all-of"/>
  <characteristic>
    <code>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/181513"/>
        <code value="SEVCO:01000"/>
        <display value="Study Design"/>
      </coding>
      <text value="Study design"/>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="http://hl7.org/fhir/study-design"/>
        <code value="SEVCO:01003"/>
        <display value="randomized assignment"/>
      </coding>
    </valueCodeableConcept>
    <exclude value="false"/>
    <description value="The study design is a randomised controlled trial."/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Study population"/>
    </code>
    <valueReference>🔗 
      <reference value="Group/265093"/>
      <type value="Group"/>
      <display value="Adults with type 2 diabetes"/>
    </valueReference>
    <exclude value="false"/>
    <description
                 value="All the participants are adults with type 2 diabetes."/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Study interventions"/>
    </code>
    <valueReference>🔗 
      <reference value="Group/265092"/>
      <type value="Group"/>
      <display value="Diabetes treatment medication"/>
    </valueReference>
    <exclude value="false"/>
    <description
                 value="The medication class should be among one or more of SGLT-2 inhibitors, GLP-1 receptr agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones, sulfonylureas, metformin, α-glucosidase inhibitors, meglitinides, insulins, dual GIP/GLP-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists."/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Duration of follow up"/>
    </code>
    <valueQuantity>
      <value value="24"/>
      <comparator value="&gt;="/>
      <unit value="weeks"/>
      <system value="http://unitsofmeasure.org"/>
      <code value="wk"/>
    </valueQuantity>
    <exclude value="false"/>
    <description
                 value="Eligible trials had a follow-up of 24 weeks or longer."/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Language of publication"/>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="urn:ietf:bcp:47"/>
        <code value="en"/>
        <display value="English"/>
      </coding>
    </valueCodeableConcept>
    <exclude value="false"/>
    <description value="We excluded non-English language published studies."/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text
            value="Systematically comparing combinations of more than one drug treatment class with no drug treatment"/>
    </valueCodeableConcept>
    <exclude value="true"/>
    <description
                 value="We excluded trials systematically comparing combinations of more than one drug treatment class with no drug treatment."/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Defined by CodeableConcept"/>
    </code>
    <valueCodeableConcept>
      <text value="Subgroup analyses"/>
    </valueCodeableConcept>
    <exclude value="true"/>
    <description
                 value="We excluded subgroup analyses of randomised controlled trials."/>
  </characteristic>
</Group>